The phase II clinical trial investigators meeting for Shanghai Yingli Pharmaceutical’s novel anti-cancer agent YY-20394 has been successfully held in Chengdu
Oct. 26, 2018, Shanghai Yingli Pharmaceutical Co., Ltd. (“Yingli Pharma”) announces today that the phase II clinical trial investigators meeting for YY-20394, a novel anti-cancer agent independently developed by Yingli Pharma, has been successfully held at Chengdu Century City New International Convention Center. The meeting was chaired by leading PI, Professor Lugui Qiu of Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. More than 40 experts from 25 hospitals were invited to attend the meeting to discuss the YY-20394 Phase II clinical trial protocol. The participating experts had thorough discussion on the preclinical data and phase I results of YL-13027 and the scientificity, feasibility and the safety of the clinical protocol, and reached an agreement on the protocol and operational procedures.
YY-20394 is a novel selective inhibitor of PI3Kδ (the delta isoform of phosphoinositide 3-kinase). A phase 1 dose escalation trial in patients with relapsed or refractory B-cell malignant hematologic tumors has been completed in China. Initial clinical trials have shown that oral administration of YY-20394 once daily induces significant clinical benefit in patients with relapsed or refractory B-cell hematologic malignancies and demonstrated higher overall response rate and better safety profile as compared to marketed products in the same class.